U.S Regenerative Medicine Market Size, Trends and Insights By Type (Cell therapy, Dermatology), By Application (Musculoskeletal segment), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2023–2032


Report Code: CMI30348

Published Date: September 2023

Pages: 220+

Category: USA

Report Snapshot

CAGR: 9.6%
213.1M
2022
244.88M
2023
530.2M
2032

Source: CMI

Study Period: 2023-2032
Fastest Growing Market: USA
Largest Market: USA

Major Players

  • Organogenesis Holding Inc
  • Abbvie Inc (Allergan Plc)
  • Intellia Therapeutics
  • Bristol Myers Squibb
  • Stryker Corporation
  • Others

Exclusive, in-depth market intelligence can help you increase your Revenue.

Download Sample Pdf

Reports Description

As per the current market research conducted by the CMI Team, the US Regenerative Medicine Market is expected to record a CAGR of 9.6% from 2023 to 2032. In 2022, the market size is projected to reach a valuation of USD 213.1 Million. By 2032, the valuation is anticipated to reach USD 530.2 Million.

The key factors propelling the growth of the market are the increasing awareness and preference for the usage of stem cells, tissue engineering, and gene therapies. The rising number of patients requiring these treatments has expanded the reach of the regenerative medicine market in the North American region.

According to medical research, at least 40,000 infants born in the U.S. each year are expected to be affected by congenital heart defects. About 25% of 2.4 (per 1,000 live births) require treatment in the first year of life. In addition, the prevalence of atrial fibrillation is estimated to rise to 12.1 million by the year 2030.

U.S. Regenerative Medicine Market – Significant Growth Factors

The increasing investment in the regenerative medicine market coupled with the prevalence of chronic diseases has provided the requisite boost to the expansion of the market in the North American region.

  • Organ failures: The rising cases of organ failure amongst the population have led to the demand for organ transplants. These health conditions arise from severe infection and heart disease amongst other reasons. Regenerative medicines are widely used in transplant procedures as they aid in the restoration of damaged tissues or entire organs.
  • Chronic diseases: The number of chronic diseases such as diabetes, ulcer, cancer, genetic disorders, and cancer are increasing rapidly. According to research by the Centers for Disease Control and Prevention (CDC), at least 26.9 million people in the U.S. are diagnosed with diabetes. They account for approximately 10.5% of the total population of the country.
  • High spending: As a result of high spending and disposable income in the U.S., its regenerative medicine market garnered a revenue of USD 15 billion in 2020. The healthcare initiatives by government bodies and private infrastructure also strengthen the market size. In 2020, the U.S. Department of Health and Human Services introduced ‘A New Vision’ which put regenerative medicine at the head of healthcare initiatives.

Overall, the increase in chronic diseases affecting the North American population and the high investment in healthcare will back the growth of the regenerative medicine market in the region.

U.S. Regenerative Medicine Market – Mergers and Acquisitions

The North American Regenerative Medicine Market has seen several mergers and acquisitions in recent years. These are seen as strategic moves by the pharma companies in a bid to expand their reach and grow their business. Some notable examples include:

  • Smith & Nephew Plc Acquisition of Osiris Therapeutics: The global medical technology business, Smith & Nephew acquired Osiris Therapeutics, Inc. in April 2019. With the acquisition, Smith & Nephews Plc hopes to expand its presence in the wound care segment.
  • AbbVie Acquisition of Allergan Plc: In May 2020, AbbVie a research-based global biopharmaceutical company acquired Allergan Plc. The move is expected to put  AbbVie in a leadership position in key areas of hematologics, Allergan aesthetics, immunology, neuroscience, and oncology.
  • Cook Biotech Acquisition of AcuityBio: In May 2021, Cook Biotech Inc., strengthened its technology portfolio by acquiring AcuityBio Inc. The latter is a developer of innovative drug-delivery combination products. This acquisition boosts both companies’ commitment to providing new therapies that improve the lives of patients suffering from lung and other types of cancers.

These mergers and acquisitions have allowed pharmaceutical companies to expand their product offerings and increase their footprint in new territories.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

U.S. Regenerative Medicine Market Regenerative Medicine Market Cell Culture Media Market for Regenerative Medicines
CAGR 9.6% (Approx) CAGR 22.8% (Approx) CAGR 12.4% (Approx)
USD 530.2 Million by 2032 USD 174. 72 Billion by 2032 USD 11799 Million by 2032

U.S. Regenerative Medicine Market – Significant Threats

The North American Regenerative Market faces several significant threats that could impact its growth and reach. Some of these threats include:

  • Expensive treatment: The technology used in manufacturing regenerative medicines, and therapies is expensive and thus affects the price factor, proving to be a deterrent to the citizens.
  • Ethical concerns: Restrictions are placed on stem cell therapy’s funding and use under the US Congress’s power to spend. One reason is that a section of the population believes that using human embryonic cells for medical research means destroying the embryo. They believe that an embryo is the start of a life.
  • Health concerns: It has come to light that adult stem cells may be unable to manipulate to produce all cell types. This limits the usage of cells in the treatment of diseases. Besides, there is the possibility that adult stem cells may contain abnormalities arising from environmental hazards, like toxins, or errors acquired by the cells during replication.

Overall, these threats pose significant challenges for the North American Regenerative Medicine Market and require bringing together manufacturers, developers, government bodies, and citizens to address concerns.

Report Scope

Feature of the Report Details
Market Size in 2023 USD 244.88 Million
Projected Market Size in 2032 USD 530.2 Million
Market Size in 2022 USD 213.1 Million
CAGR Growth Rate 9.6% CAGR
Base Year 2022
Forecast Period 2023-2032
Key Segment By Type, Application and Region
Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Country Scope US
Buying Options Request tailored purchasing options to fulfil your requirements for research.

Category-Wise Insights

By Type:

  • Cell therapy: The cell therapy segment will observe around an 18% growth rate during the forecast period, 2021-2028. This will be boosted by a growing number of clinical studies for cell therapies. In February 2021, RepliCel announced the commercialization and clinical testing of three more technologies in Japan. These technologies include two cell-based therapies one for skin regeneration and the other for tendon rejuvenation.
  • Dermatology: The dermatology segment is projected to garner the largest revenue size. Easy grafting techniques for diseases, burns, and wounds, and accessibility of a wide range of products are some of the factors for this market dominance.

By Application

  • Musculoskeletal segment: Over 30% of North America’s regenerative medicine market share in 2020 was dominated by the musculoskeletal segment. One of the important reasons for this growth is the rising prevalence of orthopaedic conditions. This is compounded by the increasing geriatric population. According to the Population Reference Bureau, the US population aged 65 and older is estimated to nearly double from 52 million in 2018 to 95 million by 2060.

US Regenerative Medicine Market 2023–2032 (By Million)

www.custommarketinsight.com

U.S. Regenerative Medicine Market – Regional Analysis

The North American regenerative medicine market can be analyzed based on government initiatives, investment in the healthcare sector, and private funding for building the infrastructure.

  • The U.S. regenerative medicine market registered USD 15 billion in revenue in 2020. Some of the reasons can be attributed to a willingness to spend on healthcare and increasing disposable income in the country.
  • The favourable inclination of the government and private research organizations to invest and boost research and development in the regenerative medicine market contributes to its growth. For instance, in 2020, the U.S. Department of Health and Human Services put forth ‘A New Vision’ that recognizes regenerative medicine as the lead of healthcare.
  • The technological progress in medical equipment has brought about a revolution in the tissue engineering and regenerative medicines segment. Several pharmaceutical companies have focused on innovative developments to provide instruments for tissue engineering, organ regeneration, regenerative medicine, and organ transplantation markets. These are attempts to push for the commercialization of surgical instruments that can make medical procedures simpler, accessible, and cost-effective.
  • Similarly, the progress made in medical automation technologies has emphasized the commercial market. As a result, the manufacturers focus on innovative regenerative medical solutions.

Overall, there is an increasing potential in the North American Regenerative Medicine Market to grow in new directions. Pharmaceutical companies are trying to innovate and come up with more measures to make the medicine procedures simpler and accessible to the population. They are aided in their effort by government bodies.

U.S. Regenerative Medicine Market – Competitive Industry Landscape

Here are some of the key players in the North American regenerative medicine market and a brief overview of each company:

  • Organogenesis Inc: Organogenesis Holdings Inc. is recognized for its portfolio of bioactive and acellular biomaterials products. It focuses on segments like surgical biologics and advanced wound care, particularly spine, orthopaedics, and degenerative conditions. The company’s sports medicine products come in aid of people dealing with musculoskeletal injuries.
  • Osiris Therapeutics (Smith & Nephew): A fast-growing company, Osiris Therapeutics manufactures products for bone grafts, articular cartilage substitutes, and skin. One of its biggest products is TruSkin, a cryopreserved, living skin allograft. It is a new option for treating chronic and large wounds.
  • AbbVie Inc., (Allergan Plc): Abbvie Inc. leads in treating several health conditions including immunology, eye care, and oncology. The company has also introduced more than 30 brands in the market. It hopes to cover big strides in drug and treatment recovery, making a positive impact on the lives of the people.
  • Cook Medical (Cook Biotech Incorporated): The company specializes in developing advanced biomaterials for site-specific tissue remodelling derived from extracellular matrices. Cook Medical is committed to providing advanced tissue repair products for improving patients’ lives. The company’s mission is to develop devices that are less invasive for patients.
  • Integra Lifesciences: A medical device manufacturing company, known globally, Integra Lifesciences manufactures products for skin regeneration, reconstructive and general surgery, and neurosurgery. It is also focused on building its portfolio through the extensive development of soft tissue reconstruction.
  • Stryker Corporation: A Fortune 500 medical technologies firm, Stryker Corporation, manufactures include implants used in joint replacement. It is a recognized name in supplying medical devices used in hospitals. It is determined to cover all aspects of healthcare, from Emergency Medical Services to Intensive Care Unit, and home care.
  • Avalon Globocare Corp: A healthcare management company, Avalon Globocare is focused on manufacturing high-impact biomedical innovation and technologies. The company works on biopreservation tools in the regenerative medicine segment and supplies chemically defined GMP media for cryopreservation. It is also dedicated to manufacturing and supplying novel clinical laboratory and diagnostics services.
  • Intellia Therapeutics: Intellia Therapeutics is a clinical-stage biotechnology firm with a focus on developing curative therapeutics through the use of CRISPR-based technologies. The company specializes in genome editing. In the pipeline are the building of in vivo and ex vivo therapies, besides its continued focus on developing modular platform capabilities.

These are some of the key players in the U.S. Regenerative Medicine Market that are known for their diverse product offerings and strong brand reputation.

The U.S Regenerative Medicine Market is segmented as follows:

By Type

  • Cell therapy
  • Dermatology

By Application

  • Musculoskeletal segment

On the basis of US Geography

  • Northeast Region
  • Southeast Region
  • Midwest Region
  • West Coast Region
  • Southwest Region
  • Mountain States

Table of Contents

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market research methodology
  • Chapter 2. Executive Summary
    • 2.1 US Regenerative Medicine Market, (2023 – 2032) (USD Million)
    • 2.2 US Regenerative Medicine Market : snapshot
  • Chapter 3. US Regenerative Medicine Market – Industry Analysis
    • 3.1 US Regenerative Medicine Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Organ failures
      • 3.2.2 Chronic diseases
      • 3.2.3 High spending
    • 3.3 Market Restraints
    • 3.4 Market Opportunities
    • 3.5 Market Challenges
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market attractiveness analysis By Type
      • 3.7.2 Market attractiveness analysis By Application
  • Chapter 4. US Regenerative Medicine Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 US Regenerative Medicine Market: company market share, 2022
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. US Regenerative Medicine Market – Type Analysis
    • 5.1 US Regenerative Medicine Market overview: By Type
      • 5.1.1 US Regenerative Medicine Market share, By Type, 2022 and 2032
    • 5.2 Cell therapy
      • 5.2.1 US Regenerative Medicine Market by Cell therapy, 2023 – 2032 (USD Million)
    • 5.3 Dermatology
      • 5.3.1 US Regenerative Medicine Market by Dermatology, 2023 – 2032 (USD Million)
  • Chapter 6. US Regenerative Medicine Market – Application Analysis
    • 6.1 US Regenerative Medicine Market overview: By Application
      • 6.1.1 US Regenerative Medicine Market share, By Application , 2022 and 2032
    • 6.2 Musculoskeletal
      • 6.2.1 US Regenerative Medicine Market by Musculoskeletal, 2023 – 2032 (USD Million)
  • Chapter 7. US Regenerative Medicine Market – Regional Analysis
    • 7.1 US Regenerative Medicine Market Regional Overview
    • 7.2 US Regenerative Medicine Market Share, by Region, 2022 & 2032 (USD Million)
  • Chapter 8. Company Profiles
    • 8.1 Organogenesis Holding Inc
      • 8.1.1 Overview
      • 8.1.2 Financials
      • 8.1.3 Product Portfolio
      • 8.1.4 Business Strategy
      • 8.1.5 Recent Developments
    • 8.2 Abbvie Inc (Allergan Plc)
      • 8.2.1 Overview
      • 8.2.2 Financials
      • 8.2.3 Product Portfolio
      • 8.2.4 Business Strategy
      • 8.2.5 Recent Developments
    • 8.3 Intellia Therapeutics
      • 8.3.1 Overview
      • 8.3.2 Financials
      • 8.3.3 Product Portfolio
      • 8.3.4 Business Strategy
      • 8.3.5 Recent Developments
    • 8.4 Bristol Myers Squibb
      • 8.4.1 Overview
      • 8.4.2 Financials
      • 8.4.3 Product Portfolio
      • 8.4.4 Business Strategy
      • 8.4.5 Recent Developments
    • 8.5 Stryker Corporation
      • 8.5.1 Overview
      • 8.5.2 Financials
      • 8.5.3 Product Portfolio
      • 8.5.4 Business Strategy
      • 8.5.5 Recent Developments
    • 8.6 Osiris Therapeutics
      • 8.6.1 Overview
      • 8.6.2 Financials
      • 8.6.3 Product Portfolio
      • 8.6.4 Business Strategy
      • 8.6.5 Recent Developments
    • 8.7 Integra LifeSciences
      • 8.7.1 Overview
      • 8.7.2 Financials
      • 8.7.3 Product Portfolio
      • 8.7.4 Business Strategy
      • 8.7.5 Recent Developments
    • 8.8 Cook Medical
      • 8.8.1 Overview
      • 8.8.2 Financials
      • 8.8.3 Product Portfolio
      • 8.8.4 Business Strategy
      • 8.8.5 Recent Developments
    • 8.9 Others.
      • 8.9.1 Overview
      • 8.9.2 Financials
      • 8.9.3 Product Portfolio
      • 8.9.4 Business Strategy
      • 8.9.5 Recent Developments
List Of Figures

Figures no 1 to 12

List Of Tables

Tables No 1 to 2

Report Methodology

In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:

Preliminary Data Mining

On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.

Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.

Statistical Model

Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.

Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.

Some of the variables taken into account for forecasting are as follows:

• Industry drivers and constraints, as well as their current and projected impact

• The raw material case, as well as supply-versus-price trends

• Current volume and projected volume growth through 2030

We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.

Primary Validation

This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.

Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.

All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:

• Market leaders

• Suppliers of raw materials

• Suppliers of raw materials

• Buyers.

The following are the primary research objectives:

• To ensure the accuracy and acceptability of our data.

• Gaining an understanding of the current market and future projections.

Data Collection Matrix

Perspective Primary research Secondary research
Supply-side
  • Manufacturers
  • Technology distributors and wholesalers
  • Company reports and publications
  • Government publications
  • Independent investigations
  • Economic and demographic data
Demand-side
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customers


Market Analysis Matrix

Qualitative analysis Quantitative analysis
  • Industry landscape and trends
  • Market dynamics and key issues
  • Technology landscape
  • Market opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2030
  • Market revenue estimates and forecasts up to 2030, by technology
  • Market revenue estimates and forecasts up to 2030, by application
  • Market revenue estimates and forecasts up to 2030, by type
  • Market revenue estimates and forecasts up to 2030, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

Prominent Player

  • Organogenesis Holding Inc
  • Abbvie Inc (Allergan Plc)
  • Intellia Therapeutics
  • Bristol Myers Squibb
  • Stryker Corporation
  • Osiris Therapeutics
  • Integra LifeSciences
  • Cook Medical
  • Others

FAQs

The key factors driving the Market are Organ failures, Chronic diseases And High spending.

The “Type” category dominated the market in 2022.

The key players in the market are Organogenesis Holding Inc, Abbvie Inc (Allergan Plc), Intellia Therapeutics, Bristol Myers Squibb, Stryker Corporation, Osiris Therapeutics, Integra LifeSciences, Cook Medical, Others.

The market is projected to grow at a CAGR of 9.6% during the forecast period, 2023-2032.

The U.S Regenerative Medicine Market size was valued at USD 213.1 Million in 2022.

PURCHASE OPTIONS

$

2650


$

3650


$

4650


$

1650


powerbi pdf
$

5200

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • Free 25% or 40 hours of customisation.
  • Free post-sale service assistance.
  • 15% discount on your next purchase.
  • Dedicated account Associate .
  • Permission to print the report.
  • Service guarantee available.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • Free 35% or 60 hours of customisation.
  • Free post-sale service assistance.
  • 25% discount on your next purchase.
  • Service guarantee available.
  • Personalised market brief by author.
  • Permission to print the report.
  • PDF, Excel and Power Point.
  • Can be accessible by unlimited users.
  • Free 40% or 80 hours of customisation.
  • Free post-sale service assistance.
  • 30% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account manager.
  • Service guarantee available.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
  • 15% discount on your next purchase.
  • Free 20% or 10 hours of customisation.
  • PDF, Excel, Power Point and Power BI.
  • Every Year Free Update ( Apr – Apr)
  • Personalized market brief by author
  • Can be accessible by unlimited users.
  • Free 50% or 90 hours of customization.
  • Up to 50 Company Profiles
  • Free post-sale service assistance with guarantee
  • 40% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account team.
  • Service guarantee available.

Want to customize this report?
100% FREE CUSTOMIZATION!